Abstract:Graves' disease (GD) is a common autoimmune disease mainly caused by thyroid-stimulating antibodies (TSAbs). Interleukin 21 (IL-21) has recently been reported to play a vital role in the production of pathogenic autoantibodies in several autoimmune diseases, but less is known about GD. This study aimed to investigate the serum levels of IL-21 in GD patients and to explore their association with disease activity. We performed a case-control association study of 152 patients with GD and 32 healthy controls. All patients were further classified into three subgroups: the GD-untreated group (n = 70), the GD-recurrence group (n = 41), and the GD-remission group (n = 41). Serum IL-21 levels were assayed with ELISA. TSAb activity was measured by an in vitro bioassay. Changes in serum IL-21 were also observed in 12 GD patients before and after treatment. Additionally, correlations among the serum IL-21 and free triiodothyronine (FT3), free thyroxine (FT4), thyrotropin (TSH), thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TGAb), thyrotropin receptor antibody (TRAb), and TSAb were also analyzed. The serum IL-21 levels in all GD patients were significantly higher than those in the control group (P < 0.001), and specifically, both the GD-untreated and GD-recurrence groups had elevated serum IL-21 compared to the control group (P < 0.001). Moreover, serum IL-21 in newly diagnosed patients markedly decreased after treatment (P < 0.001). Additionally, the serum IL-21 levels in GD-goiter patients were higher than those of the GD-non-goiter patients (P < 0.001). However, no significant differences were found in the serum IL-21 levels in patients with or without Graves' ophthalmopathy. Importantly, serum IL-21 positively correlated with FT3, FT4, TPOAb, TGAb, and TRAb (r = 0.5053, r = 0.3266, r = 0.1792, r = 0.2445, and r = 0.4096, respectively; all P < 0.0001), and particularly with TSAb activity (r = 0.8171, P < 0.0001), negatively correlated with TSH (r = -0.2713, P < 0.0001). Serum IL-21 levels were significantly elevated in patients with GD and decreased after treatment; moreover, IL-21 may be associated with the clinical disease activity. These observations suggest that IL-21 may play an important role in the pathogenesis of GD.

Constitutive Changes in Circulating Follicular Helper T Cells and Their Subsets in Patients with Graves’ Disease

Impairment of Regulatory Capacity of Cd4(+)Cd25(+) Regulatory T Cells Mediated by Dendritic Cell Polarization and Hyperthyroidism in Graves' Disease

Elevated Follicular Helper T Cells and Expression of IL-21 in Thyroid Tissues Are Involved in the Pathogenesis of Graves' Disease.

A High Frequency Of Circulating Th22 And Th17 Cells In Patients With New Onset Graves' Disease

The Role of Circulating CD4+ CD28- T Cell in the Development of Graves' Disease

Characterization and Clinical Relevance of Circulating CD4+CD28− T Cells in Graves’ Disease

CD11c+ B Cells Participate in the Pathogenesis of Graves’ Disease by Secreting Thyroid Autoantibodies and Cytokines

Phenotypic Characteristics of the CD4+CD28- T Cell Subsets in Peripheral Blood of Patients with Graves Disease and Its Clinical Significance

Association Of Graves' Disease And Prevalence Of Circulating Ifn-Gamma-Producing Cd28(-) T Cells

Advancement of Th17 lymphocyte in Graves'disease

Significance of T Cell Subsets and Expression of Costimulatory Molecule in Periph Eral Blood of Patients with Graves' Disease and Its Implication on Clinical Outcome

Elevated Interleukin-36α and CD4+IL-36α+T Cells Are Involved in the Pathogenesis of Graves' Disease.

The relationship between CD4~+ CD25~+ regulatory T cell and Graves' disease

Decreased Treg Cell and TCR Expansion Are Involved in Long-Lasting Graves’ Disease

Interleukin-21 is Associated with Disease Activity in Patients with Graves’ Disease

Expression of IFNα-inducible Genes and Modulation of HLA-DR and Thyroid Stimulating Hormone Receptors in Graves’ Disease

Different Levels of Circulating Th22 Cell and Its Related Molecules in Graves' Disease and Hashimoto's Thyroiditis.

Absolute reduction in peripheral regulatory T cells in patients with Graves’ disease and post-treatment recovery

Effects of Thyrostatic Treatment on T,B Lymphocytes and Expression of Costimulatory Molecules on Pripheral Blood Lymphocytes of Patients with Graves' Disease

Regulatory T Cells in the Pathogenesis of Graves' Disease

The increased but non-predominant expression of Th17- and Th1-specific cytokines in Hashimoto's thyroiditis but not in Graves' disease.